✦ LIBER ✦

The prevalence and influence of self-reported conflicts of interest by editorial authors of phase III cancer trials

✍ Scribed by Tatiana Goberstein Lerner; Michele da Costa Miranda; Andrea Thaumaturgo Lera; Aline Ueda; Bruna Briones; Auro Del Giglio; Rachel Riechelmann

Book ID: 118428087
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 142 KB
Volume: 33
Category: Article
ISSN: 1551-7144
DOI: 10.1016/j.cct.2012.05.011

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Influence of tumor type, disease status,

Influence of tumor type, disease status, and patient age on self-reported interest regarding participation in cancer clinical trials

✍ Maurie Markman; Judith Petersen; Robert Montgomery 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

## Abstract There is limited information available regarding the reasons cancer patients decide to enter clinical trials. To explore this issue, aggregate responses to the question, “Are you interested in learning about clinical trials for your condition?” obtained from >115,000 cancer patients (or

Who volunteers for phase I clinical tria

Who volunteers for phase I clinical trials? Influences of anxiety, social anxiety and depressive symptoms on self-selection and the reporting of adverse events

✍ Luis Almeida; Todd B. Kashdan; Teresa Nunes; Rui Coelho; António Albino-Teixeira 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 156 KB

Molecular Predictors of Outcome With Gef

Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non-Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial

✍ Douillard, J.-Y.; Shepherd, F. A.; Hirsh, V.; Mok, T.; Socinski, M. A.; Gervais, 📂 Article 📅 2010 🏛 American Society of Clinical Oncology 🌐 English ⚖ 241 KB

Long-term results of children with acute

Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891

✍ Smith, F O; Alonzo, T A; Gerbing, R B; Woods, W G; Arceci, R J 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 152 KB

Completeness in the Reporting of Dermato

Completeness in the Reporting of Dermatologic Adverse Drug Reactions Associated with Monoclonal Antibody Epidermal Growth Factor Receptor Inhibitors in Phase II and III Colorectal Cancer Clinical Trials

✍ Kimberly A. Bauer; Scott Hammerman; Bernardo Rapoport; Mario E. Lacouture 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 107 KB

Phase I/II Trial of the Addition of Erlo

Phase I/II Trial of the Addition of Erlotinib to Pre- and Postoperative Chemotherapy/Hyperfractionated Radiotherapy, and as Maintenance, for Resectable Mediastinoscopy-defined Stage III Non–small-cell Lung Cancer (NSCLC): Report on the Phase II Component

✍ G.M. Videtic; T. Rice; S. Murthy; D. Mason; P. Mazzone; N. Pennell; M. Shapiro; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 42 KB